People with a rare form of lung cancer linked to asbestos exposure have been successfully treated with a combination of Keytruda (pembrolizumab) and chemotherapy.
The Phase II/III KEYNOTE-483 trial, which was undertaken by New Jersey, USA’s Merck & Co (NYSE: MRK) together with the Canadian Cancer Trials Group (CCTG), met its primary endpoint of overall survival (OS).
The study has been exploring use of the immuno-oncology-based combo in the first-line treatment of certain people with malignant pleural mesothelioma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze